Лирентелимаб

Rec. INN (наименование, зарегистрированное ВОЗ)

DB16728

2283348-97-8

immunoglobulin G1-kappa, anti-[Homo sapiens SIGLEC8 (sialic acid binding Ig-like lectin 8, SIGLEC-8, SAF2, SIGLEC8L)], humanized monoclonal antibody;
gamma1 heavy chain humanized (1-450) [VH (Homo sapiens IGHV3-66*01 (79.4%) -(IGHD) -IGHJ5*01 (90.9%)) CDR-IMGT [8.7.14] (26-33.51-57.96-109) (1-120) -Homo sapiens IGHG1*03 (100%) G1m3, nG1m1 (CH1 R120 (217) (121-218), hinge 1-15 (219-233), CH2 (234-343), CH3 E12 (359), M14 (361) (344-448), CHS (449-450)) (121-450)], (223-213')-disulfide with kappa light chain humanized (1'-213') [V-KAPPA (Homo sapiens IGKV3-11*01 (86.3%) -IGKJ3*01 (91.7%)) CDR-IMGT [5.3.9] (27-32.50-52.89-97) (1'-107') -Homo sapiens IGKC*01 (100%) Km3 A45.1 (152), V101 (190) (108'-213')]; dimer (229-229'':232-232'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa

C₆₄₀₈H₉₈₈₄N₁₇₀₀O₂₀₀₆S₄₆

144308,221 г/моль

Поделиться этой страницей